Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.
AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.
The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.
BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint Therapeutics as a potential treatment for the correction of the loss of near vision associated with presbyopia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。